Skip to main content

Articles

Page 5 of 33

  1. Plasma amyloid-β (Aβ) peptides and tau proteins are promising biomarkers of Alzheimer’s disease (AD), not only for predicting Aβ and tau pathology but also for differentiating AD from other neurodegenerative d...

    Authors: Jingshan Chen, Xue Zhao, Wenyan Zhang, Tianxiang Zhang, Siting Wu, Jinghao Shao and Fu-Dong Shi
    Citation: Alzheimer's Research & Therapy 2023 15:100
  2. Cortical tau accumulation is a key pathological event that partly defines Alzheimer’s disease (AD) onset and is associated with cognitive decline and future disease progression. However, an improved understand...

    Authors: Antoinette O’Connor, David M. Cash, Teresa Poole, Pawel J. Markiewicz, Maggie R. Fraser, Ian B. Malone, Jieqing Jiao, Philip S. J. Weston, Shaney Flores, Russ Hornbeck, Eric McDade, Michael Schöll, Brian A. Gordon, Randall J. Bateman, Tammie L. S. Benzinger and Nick C. Fox
    Citation: Alzheimer's Research & Therapy 2023 15:99
  3. Key points of disagreement between the aducanumab FDA statistical review, which had primarily negative conclusions, and the clinical review, which had primarily positive conclusions, were investigated. Results...

    Authors: Samuel P. Dickson, Sean Hennessey, Jessie Nicodemus Johnson, Newman Knowlton and Suzanne B. Hendrix
    Citation: Alzheimer's Research & Therapy 2023 15:98
  4. White matter hyperintensities (WMH) in subjects across the Alzheimer’s disease (AD) spectrum with minimal vascular pathology suggests that amyloid pathology—not just arterial hypertension—impacts WMH, which in...

    Authors: Jose Bernal, Stefanie Schreiber, Inga Menze, Anna Ostendorf, Malte Pfister, Jonas Geisendörfer, Aditya Nemali, Anne Maass, Renat Yakupov, Oliver Peters, Lukas Preis, Luisa Schneider, Ana Lucia Herrera, Josef Priller, Eike Jakob Spruth, Slawek Altenstein…
    Citation: Alzheimer's Research & Therapy 2023 15:97
  5. Carrying the apolipoprotein E (ApoE) Ɛ4 allele is associated with an increased risk of cerebral amyloidosis and late-onset Alzheimer’s disease, but the degree to which apoE glycosylation affects its developmen...

    Authors: Cristiana J. Meuret, Yueming Hu, Sabrina Smadi, Mikaila Ann Bantugan, Haotian Xian, Ashley E. Martinez, Ronald M. Krauss, Qiu-Lan Ma, Dobrin Nedelkov and Hussein N. Yassine
    Citation: Alzheimer's Research & Therapy 2023 15:96
  6. The purpose of this study was to evaluate cholesterol esterification and HDL subclasses in plasma and cerebrospinal fluid (CSF) of Alzheimer’s disease (AD) patients.

    Authors: Marta Turri, Elisa Conti, Chiara Pavanello, Francesco Gastoldi, Marcella Palumbo, Franco Bernini, Vittoria Aprea, Francesca Re, Alberto Barbiroli, Davide Emide, Daniela Galimberti, Lucio Tremolizzo, Francesca Zimetti and Laura Calabresi
    Citation: Alzheimer's Research & Therapy 2023 15:95
  7. Neuropsychiatric symptoms (NPS) are prevalent in the early clinical stages of Alzheimer’s disease (AD) according to proxy-based instruments. Little is known about which NPS clinicians report and whether their ...

    Authors: Willem S. Eikelboom, Ellen H. Singleton, Esther van den Berg, Casper de Boer, Michiel Coesmans, Jeannette A. Goudzwaard, Everard G. B. Vijverberg, Michel Pan, Cornalijn Gouw, Merel O. Mol, Freek Gillissen, Jay L. P. Fieldhouse, Yolande A. L. Pijnenburg, Wiesje M. van der Flier, John C. van Swieten, Rik Ossenkoppele…
    Citation: Alzheimer's Research & Therapy 2023 15:94
  8. APP duplication is a rare genetic cause of Alzheimer disease and cerebral amyloid angiopathy (CAA). We aimed to evaluate the phenotypes of APP duplications carriers.

    Authors: Lou Grangeon, Camille Charbonnier, Aline Zarea, Stephane Rousseau, Anne Rovelet-Lecrux, David Bendetowicz, Marion Lemaitre, Cécile Malrain, Muriel Quillard-Muraine, Kevin Cassinari, David Maltete, Jeremie Pariente, Olivier Moreaud, Eloi Magnin, Benjamin Cretin, Marie-Anne Mackowiak…
    Citation: Alzheimer's Research & Therapy 2023 15:93
  9. Studies on DNA methylation (DNAm) in Alzheimer’s disease (AD) have recently highlighted several genomic loci showing association with disease onset and progression.

    Authors: Yasmine Sommerer, Valerija Dobricic, Marcel Schilling, Olena Ohlei, Sanaz Sedghpour Sabet, Tanja Wesse, Janina Fuß, Sören Franzenburg, Andre Franke, Laura Parkkinen, Christina M. Lill and Lars Bertram
    Citation: Alzheimer's Research & Therapy 2023 15:92
  10. Monitoring the progression of Tau pathology makes it possible to study the clinical diversity of Alzheimer’s disease. In this 2-year longitudinal PET study, we aimed to determine the progression of [18F]-flortauc...

    Authors: Julien Lagarde, Pauline Olivieri, Matteo Tonietto, Sébastian Rodrigo, Philippe Gervais, Fabien Caillé, Martin Moussion, Michel Bottlaender and Marie Sarazin
    Citation: Alzheimer's Research & Therapy 2023 15:91
  11. Brain-directed immunotherapy is a promising strategy to target amyloid-β (Aβ) deposits in Alzheimer’s disease (AD). In the present study, we compared the therapeutic efficacy of the Aβ protofibril targeting an...

    Authors: Tobias Gustavsson, Nicole G. Metzendorf, Elin Wik, Sahar Roshanbin, Ulrika Julku, Aikaterini Chourlia, Per Nilsson, Ken G. Andersson, Hanna Laudon, Greta Hultqvist, Stina Syvänen and Dag Sehlin
    Citation: Alzheimer's Research & Therapy 2023 15:90
  12. It is possible to calculate the number of years to the expected clinical onset (YECO) of autosomal-dominant Alzheimer’s disease (adAD). A similar time scale is lacking for sporadic Alzheimer’s disease (sAD). T...

    Authors: Ove Almkvist and Agneta Nordberg
    Citation: Alzheimer's Research & Therapy 2023 15:89
  13. Recruiting to multi-site trials is challenging, particularly when striving to ensure the randomized sample is demographically representative of the larger disease-suffering population. While previous studies h...

    Authors: Dylan R. Kirn, Joshua D. Grill, Paul Aisen, Karin Ernstrom, Seth Gale, Judith Heidebrink, Gregory Jicha, Gustavo Jimenez-Maggiora, Leigh Johnson, Elaine Peskind, Kelly McCann, Elizabeth Shaffer, David Sultzer, Shunran Wang, Reisa Sperling and Rema Raman
    Citation: Alzheimer's Research & Therapy 2023 15:88
  14. Therapeutic trials in Alzheimer’s disease (AD) face many obstacles—particularly with regard to screening and recruitment.

    Authors: Victoire Leroy, Wassim Gana, Amal Aïdoud, Jacques-Alexis N’kodo, Anna-Chloé Balageas, Pascal Blanc, Dominique Bomia, Camille Debacq and Bertrand Fougère
    Citation: Alzheimer's Research & Therapy 2023 15:87
  15. Subjective cognitive decline (SCD) may serve as a symptomatic indicator for preclinical Alzheimer’s disease; however, SCD is a heterogeneous entity regarding clinical progression. We aimed to investigate wheth...

    Authors: Qian Chen, Futao Chen, Cong Long, Yajing Zhu, Yaoxian Jiang, Zhengyang Zhu, Jiaming Lu, Xin Zhang, Zuzana Nedelska, Jakub Hort and Bing Zhang
    Citation: Alzheimer's Research & Therapy 2023 15:86
  16. Authors: Bruno Dubois, Jesús López‑Arrieta, Stanley Lipschitz, Triantafyllos Doskas, Luiza Spiru, Svitlana Moroz, Olena Venger, Patrick Vermersch, Alain Moussy, Colin D. Mansfield, Olivier Hermine and Magda Tsolaki
    Citation: Alzheimer's Research & Therapy 2023 15:85

    The original article was published in Alzheimer's Research & Therapy 2023 15:39

  17. Although machine learning classifiers have been frequently used to detect Alzheimer’s disease (AD) based on structural brain MRI data, potential bias with respect to sex and age has not yet been addressed. Her...

    Authors: Malte Klingenberg, Didem Stark, Fabian Eitel, Céline Budding, Mohamad Habes and Kerstin Ritter
    Citation: Alzheimer's Research & Therapy 2023 15:84
  18. The development of drugs for Alzheimer’s disease (AD), which is related to the misfolding and aggregation of amyloid-β (Aβ), is high in demand due to the growing number of AD patients. In this study, we screen...

    Authors: Rina Nakamura, Motomi Konishi, Youichirou Higashi, Motoaki Saito and Toshifumi Akizawa
    Citation: Alzheimer's Research & Therapy 2023 15:83
  19. The medial parietal cortex is an early site of pathological protein deposition in Alzheimer’s disease (AD). Previous studies have identified different subregions within this area; however, these subregions are...

    Authors: Dániel Veréb, Mite Mijalkov, Yu-Wei Chang, Anna Canal-Garcia, Emiliano Gomez-Ruis, Anne Maass, Sylvia Villeneuve, Giovanni Volpe and Joana B. Pereira
    Citation: Alzheimer's Research & Therapy 2023 15:82
  20. During COVID-19 lockdown measures, memory clinic patients reported worries for faster cognitive decline, due to loss of structure and feelings of loneliness and depression. We aimed to investigate the impact o...

    Authors: Els D. Bakker, Stéphanie L. van der Pas, Marissa D. Zwan, Freek Gillissen, Femke H. Bouwman, Philip Scheltens, Wiesje M. van der Flier and Ingrid S. van Maurik
    Citation: Alzheimer's Research & Therapy 2023 15:81
  21. Crucial to the success of clinical trials targeting early Alzheimer’s disease (AD) is recruiting participants who are more likely to progress over the course of the trials. We hypothesize that a combination of...

    Authors: Long Xie, Sandhitsu R. Das, Laura E. M. Wisse, Ranjit Ittyerah, Robin de Flores, Leslie M. Shaw, Paul A. Yushkevich and David A. Wolk
    Citation: Alzheimer's Research & Therapy 2023 15:79

    The Correction to this article has been published in Alzheimer's Research & Therapy 2024 16:11

  22. Growing evidence has demonstrated that DNA methylation (DNAm) plays an important role in Alzheimer’s disease (AD) and that DNAm differences can be detected in the blood of AD subjects. Most studies have correl...

    Authors: Wei Zhang, Juan I. Young, Lissette Gomez, Michael A. Schmidt, David Lukacsovich, Achintya Varma, X. Steven Chen, Eden R. Martin and Lily Wang
    Citation: Alzheimer's Research & Therapy 2023 15:78
  23. Alzheimer’s disease (AD) is the 5th leading cause of death in people 65 years and older. The ATN classification reflects a biological definition of AD pathology with markers of Aβ deposition (A), pathologic ta...

    Authors: Mélina Régy, Aline Dugravot, Séverine Sabia, Elodie Bouaziz-Amar, Claire Paquet, Bernard Hanseeuw, Archana Singh-Manoux and Julien Dumurgier
    Citation: Alzheimer's Research & Therapy 2023 15:77
  24. Advances in pharmacological and non-pharmacological dementia interventions may mean future dementia prevention incorporates a combination of targeted screening and lifestyle modifications. Elucidating potentia...

    Authors: Nikki-Anne Wilson, Ruth Peters, Nicola T. Lautenschlager and Kaarin J. Anstey
    Citation: Alzheimer's Research & Therapy 2023 15:76
  25. Vascular dysfunction, including cerebral hypoperfusion, plays an important role in the pathogenesis and progression of Alzheimer’s disease (AD), independent of amyloid and tau pathology. We established an AD-r...

    Authors: Meng Meng, Fang Liu, Yilong Ma, Wen Qin, Lining Guo, Shichun Peng, Marc L. Gordon, Yue Wang and Nan Zhang
    Citation: Alzheimer's Research & Therapy 2023 15:75
  26. Plasma neurofilament light (NfL) is an indicator of neurodegeneration and/or neuroaxonal injury in persons with Alzheimer’s disease (AD) and a wide range of other neurological disorders. Here, we characterized...

    Authors: Michael Malek-Ahmadi, Yi Su, Valentina Ghisays, Ji Luo, Vivek Devadas, Yinghua Chen, Wendy Lee, Hillary Protas, Kewei Chen, Henrik Zetterberg, Kaj Blennow, Richard J. Caselli and Eric M. Reiman
    Citation: Alzheimer's Research & Therapy 2023 15:74
  27. In the context of the development of pharmaceutical interventions, expectations and experiences of participants are essential. Their insights may be particularly helpful to address the challenges of recruiting...

    Authors: Lois Ottenhoff, Everard G. B. Vijverberg, Leonie N. C. Visser, Merike Verijp, Niels D. Prins, Wiesje M. Van der Flier and Sietske A. M. Sikkes
    Citation: Alzheimer's Research & Therapy 2023 15:72
  28. Neuroinflammation, characterized by increased reactivity of microglia and astrocytes in the brain, is known to be present at various stages of the Alzheimer’s disease (AD) continuum. However, its presence and rel...

    Authors: Anniina Snellman, Laura L. Ekblad, Jouni Tuisku, Mikko Koivumäki, Nicholas J. Ashton, Juan Lantero-Rodriguez, Thomas K. Karikari, Semi Helin, Marco Bucci, Eliisa Löyttyniemi, Riitta Parkkola, Mira Karrasch, Michael Schöll, Henrik Zetterberg, Kaj Blennow and Juha O. Rinne
    Citation: Alzheimer's Research & Therapy 2023 15:71
  29. There is a need for a reliable, easy-to-use, widely available, and validated tool for timely cognitive impairment identification. We created a computerized cognitive screening tool (Santé-Cerveau digital tool ...

    Authors: Constance Lesoil, Stéphanie Bombois, Octave Guinebretiere, Marion Houot, Mahsa Bahrami, Marcel Levy, Rémy Genthon, Frédérique Bozon, Heidy Jean-Marie, Stéphane Epelbaum, Pierre Foulon, Nicolas Villain and Bruno Dubois
    Citation: Alzheimer's Research & Therapy 2023 15:70
  30. Previous studies have suggested a correlation between elevated levels of β2-microglobulin (B2M) and cognitive impairment. However, the existing evidence is insufficient to establish a conclusive relationship. Thi...

    Authors: Yi-Ming Huang, Ya-Hui Ma, Pei-Yang Gao, Zhi-Bo Wang, Liang-Yu Huang, Jia-Hui Hou, Lan Tan and Jin-Tai Yu
    Citation: Alzheimer's Research & Therapy 2023 15:69
  31. A growing body of evidence shows differences in the prevalence of cardiometabolic syndrome (CMS) and dementia based on gender and ethnicity. However, there is a paucity of information about ethnic- and gender-...

    Authors: Sung Hoon Kang, Mengting Liu, Gilsoon Park, Sharon Y. Kim, Hyejoo Lee, William Matloff, Lu Zhao, Heejin Yoo, Jun Pyo Kim, Hyemin Jang, Hee Jin Kim, Neda Jahanshad, Kyumgmi Oh, Seong-Beom Koh, Duk L. Na, John Gallacher…
    Citation: Alzheimer's Research & Therapy 2023 15:68
  32. Individuals from minority ethnic groups in the UK are thought to be at higher risk of developing dementia while facing additional barriers to receiving timely care. However, few studies in the UK have examined...

    Authors: Melissa Co, Christoph Mueller, Rosie Mayston, Jayati Das-Munshi and Matthew Prina
    Citation: Alzheimer's Research & Therapy 2023 15:67
  33. Both Alzheimer’s disease (AD) genetic risk factors and indices of cognitive reserve (CR) influence risk of cognitive decline, but it remains unclear whether they interact. This study examined whether a CR inde...

    Authors: Corinne Pettigrew, Jurijs Nazarovs, Anja Soldan, Vikas Singh, Jiangxia Wang, Timothy Hohman, Logan Dumitrescu, Julia Libby, Brian Kunkle, Alden L. Gross, Sterling Johnson, Qiongshi Lu, Corinne Engelman, Colin L. Masters, Paul Maruff, Simon M. Laws…
    Citation: Alzheimer's Research & Therapy 2023 15:66
  34. The use of music interventions as a non-pharmacological therapy to improve cognitive and behavioral symptoms in Alzheimer’s disease (AD) patients has gained popularity in recent years, but the evidence for the...

    Authors: Malak Bleibel, Ali El Cheikh, Najwane Said Sadier and Linda Abou-Abbas
    Citation: Alzheimer's Research & Therapy 2023 15:65
  35. Aβ42/Aβ40 ratios in cerebrospinal fluid (CSF) and blood are reduced in preclinical Alzheimer’s disease (AD), but their temporal and correlative relationship with cerebral Aβ pathology at this early disease sta...

    Authors: Emelie Andersson, Nina Schultz, Takashi Saito, Takaomi C. Saido, Kaj Blennow, Gunnar K. Gouras, Henrik Zetterberg and Oskar Hansson
    Citation: Alzheimer's Research & Therapy 2023 15:64
  36. Authors: Francesca Conca, Valentina Esposito, Francesco Rundo, Davide Quaranta, Cristina Muscio, Rosa Manenti, Giulia Caruso, Ugo Lucca, Alessia Antonella Galbussera, Sonia Di Tella, Francesca Baglio, Federica L’Abbate, Elisa Canu, Valentina Catania, Massimo Filippi, Giulia Mattavelli…
    Citation: Alzheimer's Research & Therapy 2023 15:63

    The original article was published in Alzheimer's Research & Therapy 2022 14:113

  37. Loss of synaptic functionality has been recently identified as an early-stage indicator of neurological diseases. Consequently, monitoring changes in synaptic protein levels may be relevant for observing disea...

    Authors: Shreyasee Das, Julie Goossens, Dirk Jacobs, Nele Dewit, Yolande A. L. Pijnenburg, Sjors G. J. G. In ‘t Veld, Charlotte E. Teunissen and Eugeen Vanmechelen
    Citation: Alzheimer's Research & Therapy 2023 15:62
  38. Connectome mapping may reveal new treatment targets for patients with neurological and psychiatric diseases. However, the long-term delayed recall based-network with structural and functional connectome is sti...

    Authors: Jie Ma, Mou-Xiong Zheng, Jia-Jia Wu, Xiang-Xin Xing, Yun-Ting Xiang, Dong Wei, Xin Xue, Han Zhang, Xu-Yun Hua, Qi-Hao Guo and Jian-Guang Xu
    Citation: Alzheimer's Research & Therapy 2023 15:61
  39. Alzheimer’s disease (AD) is a major global health crisis in need of more effective therapies. However, difficult choices to optimize value-based care will need to be made. While identifying preferred therapeut...

    Authors: George Dranitsaris, Quanwu Zhang, Lin Mu, Christopher Weyrer, Erik Drysdale, Peter Neumann, Alireza Atri and Amir Abbas Tahami Monfared
    Citation: Alzheimer's Research & Therapy 2023 15:60
  40. Frontotemporal lobar degeneration (FTLD) is characterized pathologically by neuronal and glial inclusions of hyperphosphorylated tau or by neuronal cytoplasmic inclusions of TDP43. This study aimed at decipher...

    Authors: Claire Bridel, Juami H. M. van Gils, Suzanne S. M. Miedema, Jeroen J. M. Hoozemans, Yolande A. L. Pijnenburg, August B. Smit, Annemieke J. M. Rozemuller, Sanne Abeln and Charlotte E. Teunissen
    Citation: Alzheimer's Research & Therapy 2023 15:59
  41. Cortical and subcortical microstructural modifications are critical to understanding the pathogenic changes in frontotemporal lobar degeneration (FTLD) subtypes. In this study, we investigated cortical and sub...

    Authors: Wencai Ding, Peng Ren, Liye Yi, Yao Si, Fan Yang, Zhipeng Li, Hongbo Bao, Shi Yan, Xinyu Zhang, Siyang Li, Xia Liang and Lifen Yao
    Citation: Alzheimer's Research & Therapy 2023 15:58
  42. Midlife hypertension has been recognized as a modifiable risk factor for dementia, but association between blood pressure (BP) in late life and dementia has been inconclusive. In addition, few studies have inv...

    Authors: Mi Hee Cho, Kyungdo Han, Seungwoo Lee, Su-Min Jeong, Jung Eun Yoo, SangYun Kim, Jinkook Lee, Sohyun Chun and Dong Wook Shin
    Citation: Alzheimer's Research & Therapy 2023 15:56
  43. Insulin resistance (IR) and type 2 diabetes have been found to increase the risk for Alzheimer’s clinical syndrome in epidemiologic studies but have not been associated with tau tangles in neuropathological re...

    Authors: Gilda E. Ennis, Tobey J. Betthauser, Rebecca Langhough Koscik, Nathaniel A. Chin, Bradley T. Christian, Sanjay Asthana, Sterling C. Johnson and Barbara B. Bendlin
    Citation: Alzheimer's Research & Therapy 2023 15:55
  44. The relationship between biomarkers of metabolic syndrome and insulin resistance, plasma triglyceride/HDL cholesterol (TG/HDL-C) ratio, on the rate of cognitive decline in mild cognitive impairment (MCI) and d...

    Authors: Jagan A. Pillai, James Bena, Lynn Bekris, Nandan Kodur, Takhar Kasumov, James B. Leverenz and Sangeeta R. Kashyap
    Citation: Alzheimer's Research & Therapy 2023 15:54
  45. Alzheimer’s disease (AD) and osteoporosis are two distinct diseases but often occur in the same patient. Their relationship remains poorly understood. Studies using Tg2576 AD animal model demonstrate bone defi...

    Authors: Li Chen, Lei Xiong, Lingling Yao, Jinxiu Pan, Emily Arzola, Xiaojuan Zhu, Lin Mei and Wen-Cheng Xiong
    Citation: Alzheimer's Research & Therapy 2023 15:53
  46. A key histopathological hallmark of Alzheimer’s disease (AD) is the presence of neurofibrillary tangles of aggregated microtubule-associated protein tau in neurons. Anle138b is a small molecule which has previ...

    Authors: Layla Hosseini-Gerami, Elena Ficulle, Neil Humphryes-Kirilov, David C. Airey, James Scherschel, Sarubini Kananathan, Brian J. Eastwood, Suchira Bose, David A. Collier, Emma Laing, David Evans, Howard Broughton and Andreas Bender
    Citation: Alzheimer's Research & Therapy 2023 15:52
  47. CSF-soluble platelet-derived growth factor receptor beta (sPDGFRβ) is closely associated with pericyte damage. However, the changes in CSF sPDGFRβ levels and their role in bloodbrain barrier (BBB) leakage at dif...

    Authors: Xinyi Lv, Mengguo Zhang, Zhaozhao Cheng, Qiong Wang, Peng Wang, Qiang Xie, Ming Ni, Yong Shen, Qiqiang Tang and Feng Gao
    Citation: Alzheimer's Research & Therapy 2023 15:51